JPRN-jRCT2031220066招募中未知
Post-marketing surveillance of Raiatt MIBG-I 131 Injection (all-case surveillance)
Bando Kazunori0 个研究点目标入组 70 人开始时间: 2022年5月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •All patients who received Raiatt MIBG-I 131 Injection
排除标准
- 未提供
研究者
相似试验
已完成
Unknown
Prospective, Post Marketing Surveillance of RECTABUL2mg rectal formlcerative colitis (except for severe disease)JPRN-jRCT1080223802EA Pharma Co.,Ltd.600
未知
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-investigation of the clinical condition in patients with changing from botulinum toxin type Acervical dystoniaJPRN-jRCT1080222128Eisai Co., Ltd.150
已完成
Unknown
Post-marketing surveillance of administration of botulinum toxin type B(NerBloc)-Investigation of the clinical condition and safety in patients with cervical dystoniacervical dystoniaJPRN-jRCT1080222127Eisai Co., Ltd.
已完成
不适用
Post-marketing surveillance of Vadadustat in patients with anemia in chronic kidney disease for long-term efficacy and safetyRenal anemiaJPRN-UMIN000042349Mitsubishi Tanabe Pharma Corporation2,000
招募中
4 期
Evaluation of AryoTrust administration in treatment of breast cancerIRCT20150303021315N16Aryogen597